Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 820

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 820
---
 December 31, 2024.

Warrants - The following
table summarizes the Company’s outstanding common stock warrants as of December 31, 2024.

F-88

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

|                                                        |     | Outstanding |            |     | Weighted       
 average        
 exercise price |          |     | Expiration dates             |
|:-------------------------------------------------------|:----|:------------|-----------:|:----|:---------------|---------:|:----|:-----------------------------|
| Historical TuHURA common stock warrants                |     |             | 10,592,387 |     | $              |     4.16 |     | February 2025 to August 2029 |
| Historical Kintara common stock warrants               |     |             |     17,468 |     | $              | 1,362.41 |     | March 2025 to April 2027     |
| 2024 common stock warrants issued to financial advisor |     |             |    297,029 |     | $              |     0.01 |     | April 2027                   |

Warrant modification In August 2024, the Company extended the exercise period of its common stock purchase warrants issued in connection with Legacy TuHURA Series A Preferred Stock (the “Series A Warrants”) for an additional six months, with a new expiry date of February 12, 2025. There were no other changes in the terms of the Series A Warrants. As a result, a deemed dividend to the holders of the Series A Warrants in the amount of $965,177 was recorded as an increase in the net loss attributable to the common stockholders for the year ended December 31, 2024. The incremental value associated with the warrant modification was determined using a Black-Sholes pricing model using the original terms of the warrants and the modified terms of the warrants and the following assumptions: expected term of approximately 0.1 - 0.6 years, dividend yield of 0.0%, volatility of 75% -112%,and a risk free rate of 5.4% to 5.5%. Financial advisor warrants There were 297,029 warrants issued to our financial advisor, H.C. Wainwright & Co., LLC., related to merger transaction costs in connection with the reverse merger with